Vernal Conjunctivitis Treatment
For vernal conjunctivitis, initiate treatment with environmental modifications, cool compresses, and ocular lubricants, combined with topical antihistamines and mast-cell stabilizers for maintenance; for acute exacerbations, topical corticosteroids are necessary, and cyclosporine 0.1% is the FDA-approved first-line topical immunomodulator for both children and adults with VKC. 1
Stepwise Treatment Algorithm
First-Line: Conservative Measures + Maintenance Therapy
- Environmental control: Minimize allergen exposure in hot, dry environments (VKC is prevalent in these climates)
- Cool compresses and preservative-free artificial tears (refrigerated for added comfort)
- Topical antihistamines and mast-cell stabilizers for ongoing symptom control
- Oral antihistamines can be added but may worsen dry eye 1
Second-Line: Acute Exacerbations
Topical corticosteroids are usually necessary to control severe symptoms and signs during acute flares (1-2 week courses with low side-effect profile steroids). 1 This is a strong recommendation with moderate evidence quality.
Third-Line: Steroid-Sparing Immunomodulators
Cyclosporine 0.1% is the first and only FDA-approved topical immunomodulator specifically for VKC in children and adults. 1 This is critical because:
- It reduces signs and symptoms within 2 weeks
- Prevents seasonal recurrences when used at least 4 times daily (0.05% formulation)
- Allows reduced topical steroid use, minimizing glaucoma and cataract risk 1
Alternative immunomodulators include:
- Tacrolimus (off-label): Effective in steroid-refractory cases 1
- Interferon-alpha-2b: For cases not responding to steroids 1
Fourth-Line: Severe, Sight-Threatening Disease
For severe VKC unresponsive to topical therapy, supratarsal corticosteroid injection can be considered. 1
Critical Monitoring Requirements
If using corticosteroids chronically, perform baseline and periodic IOP measurements and pupillary dilation to screen for glaucoma and cataract. 1 This is non-negotiable given the young age of most VKC patients.
Control eye rubbing aggressively—VKC is associated with keratoconus progression, and adequate allergy control reduces ectasia risk. 1
Important Clinical Pitfalls
- Do not delay immunomodulator therapy: VKC can cause corneal neovascularization, ulceration, scarring, limbal stem cell deficiency, and permanent vision loss 1
- Avoid chronic steroid monotherapy: The pediatric population is at high risk for steroid-induced glaucoma and cataracts
- VKC has a chronic course with acute exacerbations during spring/summer, lasting 2-20 years before gradual resolution 1
- Potential sequelae include eyelid thickening, ptosis, conjunctival scarring, corneal complications, and visual loss 1
Emerging Evidence
Recent case reports suggest potential benefit from systemic JAK inhibitors (upadacitinib) in refractory VKC coexisting with atopic dermatitis 2, though this remains investigational. Immunotherapy may reduce topical steroid dependence in select cases 3.